Multi-center, Two-arm Non-comparative, Observational, 96-week Phase IV Study to Evaluate Treatment Adherence When Using RebiSmart for Self-injection of Rebif in Multi-dose Cartridges in Subjects With Relapsing Multiple Sclerosis (RMS).

Trial Profile

Multi-center, Two-arm Non-comparative, Observational, 96-week Phase IV Study to Evaluate Treatment Adherence When Using RebiSmart for Self-injection of Rebif in Multi-dose Cartridges in Subjects With Relapsing Multiple Sclerosis (RMS).

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Apr 2016

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms MEASURE
  • Sponsors EMD Serono; Merck KGaA
  • Most Recent Events

    • 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology
    • 08 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Feb 2013 Planned end date changed from 1 Mar 2015 to 1 Jul 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top